MarketCap
Facebook
X
Telegram
Biogen Gross Profit | BIIB
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Biogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 12.4 B | 11.6 B | 10.6 B | 9.97 B | 9.52 B | 8.53 B | 6.07 B | 4.97 B | 4.58 B | 1.12 B | 1.03 B | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.4 B | 1.03 B | 7.32 B |
Quarterly Gross Profit Biogen
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.36 B | 2.93 B | 3.27 B | 3.08 B | 3.22 B | 3.17 B | 3.14 B | 2.89 B | 3.04 B | 2.98 B | 2.94 B | 2.69 B | 2.8 B | 2.71 B | 2.71 B | 2.43 B | 2.49 B | 2.54 B | 2.52 B | 2.41 B | 2.51 B | 2.47 B | 2.31 B | 2.24 B | 2.34 B | 2.21 B | 2.13 B | 1.85 B | 1.71 B | 1.59 B | 1.49 B | 1.28 B | 1.28 B | 1.25 B | 1.28 B | 1.16 B | 1.19 B | 1.19 B | 1.11 B | 1.1 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.27 B | 1.1 B | 2.25 B |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Outlook Therapeutics
OTLK
|
57.2 K | $ 0.6 | 0.42 % | $ 20.9 M |  USA |
 |
Ovid Therapeutics
OVID
|
12.6 K | $ 2.34 | 0.21 % | $ 305 M | USA |
 |
Puma Biotechnology
PBYI
|
235 M | $ 9.67 | 1.68 % | $ 484 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
5 K | $ 1.49 | 0.62 % | $ 1.95 M | USA |
 |
Pfizer
PFE
|
41.5 B | $ 27.41 | 0.02 % | $ 156 B | USA |
 |
Precigen
PGEN
|
29.3 M | $ 7.74 | 4.02 % | $ 2.42 B | USA |
 |
Pharming Group N.V.
PHAR
|
113 M | $ 9.8 | 0.51 % | $ 6.75 B |  Niderland |
 |
Phathom Pharmaceuticals
PHAT
|
153 M | $ 6.7 | 1.77 % | $ 489 M | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
4.36 K | $ 0.99 | 0.6 % | $ 5.92 M | USA |
 |
Pliant Therapeutics
PLRX
|
41.8 K | $ 1.03 | 0.48 % | $ 63.2 M | USA |
 |
Protalix BioTherapeutics
PLX
|
43.8 M | $ 2.71 | 0.37 % | $ 213 M |  Israel |
 |
ProQR Therapeutics N.V.
PRQR
|
313 K | $ 1.67 | 2.14 % | $ 176 M | Niderland |
 |
PTC Therapeutics
PTCT
|
295 M | $ 63.65 | 0.3 % | $ 5.06 B | USA |
 |
Pulmatrix
PULM
|
12.6 K | $ 1.48 | 0.64 % | $ 5.41 B | USA |
 |
uniQure N.V.
QURE
|
9.67 M | $ 22.8 | 0.39 % | $ 1.31 B | Niderland |
 |
Regeneron Pharmaceuticals
REGN
|
7.08 B | $ 726.47 | 0.05 % | $ 76 B | USA |
 |
REGENXBIO
RGNX
|
27 M | $ 7.76 | 4.44 % | $ 400 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
58.4 M | $ 47.79 | 1.36 % | $ 860 M | USA |
|
Rezolute
RZLT
|
-4.84 K | $ 4.33 | 7.98 % | $ 450 M | USA |
 |
Seer
SEER
|
8.46 M | $ 2.33 | 3.56 % | $ 129 M | USA |
 |
SIGA Technologies
SIGA
|
11.7 M | $ 3.48 | 2.96 % | $ 249 M | USA |
|
Silence Therapeutics plc
SLN
|
15.1 M | $ 10.14 | 0.78 % | $ 1.44 B |  Britain |
 |
SELLAS Life Sciences Group
SLS
|
1.9 K | $ 11.63 | 3.62 % | $ 1.27 B | USA |
 |
Summit Therapeutics
SMMT
|
56.4 M | $ 17.27 | 3.07 % | $ 12.9 B | Britain |
 |
Syndax Pharmaceuticals
SNDX
|
627 K | $ 17.83 | 1.31 % | $ 1.54 B | USA |
 |
Soligenix
SNGX
|
97.3 K | $ 0.36 | 0.6 % | $ 1.87 M | USA |
 |
Sanofi
SNY
|
33.7 B | $ 39.51 | 1.19 % | $ 48.2 B |  France |